Firing up for FOBs

Generic drug and biotech companies maneuvered behind the scenes last week to drum up high level support for their positions on follow-on biologics legislation. The issue will break out into the daylight soon with the introduction of legislation and an official estimate of the potential cost savings.

The Democratic Party’s ascendancy to majority status in Congress has sparked a flurry of activity on follow-on biologics (FOBs), accelerating efforts to create a legal framework for abbreviated reviews of proteins based on their comparability to approved versions...